Therefore, the reduced inhibition of JAK2 and JAK3-dependent cytokine signaling pathways by filgotinib may theoretically explain its improved tolerability profile, as observed in RA phase 3 studies (Table 2). The gene discussed is JAK3; the disease is rheumatoid arthritis.